BARDINI MICHELA

Ruolo: 
Assegnista di ricerca
Settore scientifico disciplinare: 
PEDIATRIA GENERALE E SPECIALISTICA (MED/38)

Pubblicazioni

  • Agraz-Doblas, A., Bueno, C., Bashford-Rogers, R., Roy, A., Schneider, P., Bardini, M., et al. (2019). Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. HAEMATOLOGICA. Dettaglio
  • Magnani, C., Mezzanotte, C., Cappuzzello, C., Bardini, M., Tettamanti, S., Fazio, G., et al. (2018). Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia. HUMAN GENE THERAPY, 29(5), 602-613. Dettaglio
  • Bardini, M., Trentin, L., Rizzo, F., Vieri, M., Savino, A., Castro, P., et al. (2018). Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4+ infant ALL. MOLECULAR CANCER THERAPEUTICS, 17(8), 1705-1716. Dettaglio
  • Prieto, C., López-Millán, B., Roca-Ho, H., Stam, R., Romero-Moya, D., Rodríguez-Baena, F., et al. (2018). NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. LEUKEMIA, 32(3), 633-644. Dettaglio
  • Prieto, C., Lopez-Millan, B., Roca-Ho, H., Stam, R., Romero-Moya, D., Rodriguez-Baena, F., et al. (2018). Correction to: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL (Leukemia, (2018), 32, 3, (633-644), 10.1038/leu.2017.294) [Altro]. Dettaglio